|
1
|
Ott JJ, Stevens GA, Groeger J and Wiersma
ST: Global epidemiology hepatitis B virus infection: New estimates
of age-specific HBsAg seroprevalence and endemicity. Vaccine.
30:2212–2219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lavanchy D: Hepatitis B virus
epidemiology, disease burden, treatment, and current and emerging
prevention and control measures. J Viral Hepat. 11:97–107. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Geretti AM, Patel M, Sarfo FS, Chadwick D,
Verheyen J, Fraune M, Garcia A and Phillips RO: Detection of highly
prevalent hepatitis B virus coinfection among HIV-seropositive
persons in Ghana. J Clin Microbiol. 48:3223–3230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY,
Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, et
al: Long-term safety of lamivudine treatment in patients with
chronic hepatitis B. Gastroenterology. 125:1714–1722. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim HJ, Park JH, Park DI, Cho YK, Sohn CI,
Jeon WK and Kim BI: Rescue therapy for lamivudine-resistant chronic
hepatitis B: Comparison between entecavir 1.0 mg monotherapy,
adefovir monotherapy and adefovir add-on lamivudine combination
therapy. J Gastroenterol Hepatol. 25:1374–1380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perrillo R, Hann HW, Mutimer D, Willems B,
Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, et al:
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis
B with YMDD mutant hepatitis B virus. Gastroenterology. 126:81–90.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vassiliadis TG, Giouleme O, Koumerkeridis
G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N,
Mpoumponaris A, Gkisakis D, Theodoropoulos K, et al: Adefovir plus
lamivudine are more effective than adefovir alone in
lamivudine-resistant HBeAg-chronic hepatitis B patients: A 4-year
study. J Gastroenterol Hepatol. 25:54–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM,
Lee HC, Chung YH, Lee YS, Yoo W and Kim SO: Increased risk of
adefovir resistance in patients with lamivudine-resistant chronic
hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
Hepatology. 43:1385–1391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou B, Dong H, He Y, Sun J, Jin W, Xie Q,
Fan R, Wang M, Li R, Chen Y, et al: Composition and interactions of
hepatitis B virus quasispecies defined the virological response
during telbivudine therapy. Sci Rep. 5:171232015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Domingo E and Gomez J: Quasispecies and
its impact on viral hepatitis. Virus Res. 127:131–150. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan X, Mao Q, Zhou D, Lu Y, Xing J, Xu Y,
Ray SC and Di Bisceglie AM: High diversity of hepatitis C viral
quasispecies is associated with early virological response in
patients undergoing antiviral therapy. Hepatology. 50:1765–1772.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sherman KE, Rouster SD, Stanford S,
Blackard JT, Shire N, Koziel M, Peters M and Chung RT;: AIDS
Clinical Trials Group 5071 Study Team: Hepatitis C virus (HCV)
quasispecies complexity and selection in HCV/HIV-coinfected
subjects treated with interferon-based regimens. J Infect Dis.
201:712–719. 2010.PubMed/NCBI
|
|
13
|
Chen L, Zhang Q, Yu DM, Wan MB and Zhang
XX: Early changes of hepatitis B virus quasispecies during
lamivudine treatment and the correlation with antiviral efficacy. J
Hepatol. 50:895–905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu F, Chen L, Yu DM, Deng L, Chen R,
Jiang Y, Chen L, Huang SY, Yu JL, Gong QM and Zhang XX:
Evolutionary patterns of hepatitis B virus quasispecies under
different selective pressures: Correlation with antiviral efficacy.
Gut. 60:1269–1277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peveling-Oberhag J, Herrmann E,
Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S and
Hofmann WP: Dynamics of hepatitis B virus quasispecies
heterogeneity and virologic response in patients receiving
low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat.
20:234–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin F, Wu Z, Fang W, Wu C, Rayner S, Han
M, Deng F, Du R, Liu J, Wang M, et al: Resistant mutations and
quasispecies complexity of hepatitis B virus during telbivudine
treatment. J Gen Virol. 96:3302–3312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sheldon J and Soriano V: Hepatitis B virus
escape mutants induced by antiviral therapy. J Antimicrob
Chemother. 61:766–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen CH, Lee CM, Tung WC, Wang JH, Hung
CH, Hu TH, Wang JC, Lu SN and Changchien CS: Evolution of
full-length HBV sequences in chronic hepatitis B patients with
sequential lamivudine and adefovir dipivoxil resistance. J Hepatol.
52:478–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu H, Wang C, Zhang Y, Wei S, Li X and
Zhang Z: Prediction model for sustained hepatitis B e antigen
seroconversion to peginterferon alfa-2a in chronic hepatitis B. J
Gastroenterol Hepatol. 31:1963–1970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hall TA: BioEdit: A user-friendly
biological sequence alignment editor and analysis program for
Windows 95/98/NT. Nucl Acids Symp Ser. 41:95–98. 1999.
|
|
21
|
Thompson JD, Gibson TJ, Plewniak F,
Jeanmougin F and Higgins DG: The CLUSTAL_X windows interface:
Flexible strategies for multiple sequence alignment aided by
quality analysis tools. Nucleic Acids Res. 25:4876–4882. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martin D and Rybicki E: RDP: Detection of
recombination amongst aligned sequences. Bioinformatics.
16:562–563. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Domingo E, Martin V, Perales C,
Grande-Pérez A, Garcia-Arriaza J and Arias A: Viruses as
quasispecies: Biological implications. Curr Top Microbiol Immunol.
299:51–82. 2006.PubMed/NCBI
|
|
24
|
Kumar S, Stecher G and Tamura K: MEGA7:
Molecular evolutionary genetics analysis version 7.0 for bigger
datasets. Mol Biol Evol. 33:1870–1874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng X, Wang J and Yang D: Antiviral
therapy for chronic hepatitis B in China. Med Microbiol Immunol.
204:115–120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J,
Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, et al: Evaluating the
efficacy of switching from lamivudine plus adefovir to tenofovir
disoproxil fumarate monotherapy in lamivudine-resistant stable
hepatitis B patients. PLoS One. 13:e01905812018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Keeffe EB, Zeuzem S, Koff RS, Dieterich
DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N,
Marcellin P, et al: Report of an international workshop: Roadmap
for management of patients receiving oral therapy for chronic
hepatitis B. Clin Gastroenterol Hepatol. 5:890–897. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng Y, Guindon S, Rodrigo A and Lim SG:
Increased viral quasispecies evolution in HBeAg seroconverter
patients treated with oral nucleoside therapy. J Hepatol.
58:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han Y, Gong L, Sheng J, Liu F, Li XH, Chen
L, Yu DM, Gong QM, Hao P and Zhang XX: Prediction of virological
response by pretreatment hepatitis B virus reverse transcriptase
quasispecies heterogeneity: The advantage of using next-generation
sequencing. Clin Microbiol Infect. 21:797.e1–e8. 2015. View Article : Google Scholar
|
|
30
|
Chen L, Gan QR, Zhang DQ, Yao LF, Lin RS,
Li Q, Lin MH, Yu DM, Zhang XX and Pan C: Increased intrahepatic
quasispecies heterogeneity correlates with off-treatment sustained
response to nucleos(t)ide analogues in e antigen-positive chronic
hepatitis B patients. Clin Microbiol Infect. 22:201–207. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lavocat F, Dény P, Pichoud C, Al Hawajri
N, Kitrinos K, Borroto-Esoda K and Zoulim F: Similar evolution of
hepatitis B virus quasispecies in patients with incomplete adefovir
response receiving tenofovir/emtricitabine combination or tenofovir
monotherapy. J Hepatol. 59:684–695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ijaz S, Arnold C, Dervisevic S, Mechurova
J, Tatman N, Tedder RS and Naoumov NV: Dynamics of
lamivudine-resistant hepatitis B virus during adefovir monotherapy
versus lamivudine plus adefovir combination therapy. J Med Virol.
80:1160–1170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Villet S, Pichoud C, Billioud G, Barraud
L, Durantel S, Trépo C and Zoulim F: Impact of hepatitis B virus
rtA181V/T mutants on hepatitis B treatment failure. J Hepatol.
48:747–755. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lapiński TW, Pogorzelska J and Flisiak R:
HBV mutations and their clinical significance. Adv Med Sci.
57:18–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang ZH, Wu CC, Chen XW, Li X, Li J and
Lu MJ: Genetic variation of hepatitis B virus and its significance
for pathogenesis. World J Gastroenterol. 22:126–144. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sheldon J, Camino N, Rodés B,
Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T,
Klausen G, et al: Selection of hepatitis B virus polymerase
mutations in HIV-coinfected patients treated with tenofovir.
Antivir Ther. 10:727–734. 2005.PubMed/NCBI
|
|
37
|
Coppola N, Onorato L, Minichini C, Di
Caprio G, Starace M, Sagnelli C and Sagnelli E: Clinical
significance of hepatitis B surface antigen mutants. World J
Hepatol. 7:2729–2739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang ML and Tang H: Nucleos(t)ide
analogues causes HBV S gene mutations and carcinogenesis.
Hepatobiliary Pancreat Dis Int. 15:579–586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amini-Bavil-Olyaee S, Vucur M, Luedde T,
Trautwein C and Tacke F: Differential impact of immune escape
mutations G145R and P120T on the replication of
lamivudine-resistant hepatitis B virus e antigen-positive and
-negative strains. J Virol. 84:1026–1033. 2010. View Article : Google Scholar : PubMed/NCBI
|
